Anticholesteremic Agents

• 

  Subject Areas on Research

  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. 
  • A note on sample size calculation for mean comparisons based on noncentral t-statistics. 
  • ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK. 
  • Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. 
  • Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. 
  • Achievement of recommended lipid and lipoprotein levels with combined ezetimibe/statin therapy versus statin alone in patients with and without diabetes. 
  • Adsorption of clofibric acid and ketoprofen onto powdered activated carbon: effect of natural organic matter. 
  • Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial. 
  • Alirocumab after acute coronary syndrome in patients with a history of heart failure. 
  • Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. 
  • Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab. 
  • Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. 
  • Association between statin use and uveitis: results from the Pacific Ocular Inflammation study. 
  • Association of Osteopontin, Neopterin, and Myeloperoxidase With Stroke Risk in Patients With Prior Stroke or Transient Ischemic Attacks: Results of an Analysis of 13 Biomarkers From the Stroke Prevention by Aggressive Reduction in Cholesterol Levels Trial. 
  • Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT. 
  • Bayesian analysis of multi-type recurrent events and dependent termination with nonparametric covariate functions. 
  • Benefit of Ezetimibe Added to Simvastatin in Reduced Kidney Function. 
  • Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. 
  • Can group medical clinics improve lipid management in diabetes? 
  • Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. 
  • Changes in Medical Management after Coronary CT Angiography. 
  • Children with Heterozygous Familial Hypercholesterolemia in the United States: Data from the Cascade Screening for Awareness and Detection-FH Registry. 
  • Cholesterol-lowering medication and relapse of depression. 
  • Clinical reasoning and prevention of cardiovascular disease. 
  • Co-medications that modulate liver injury and repair influence clinical outcome of acetaminophen-associated liver injury. 
  • Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry. 
  • Determining When to Add Nonstatin Therapy: A Quantitative Approach. 
  • Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. 
  • Effect of atorvastatin in elderly patients with a recent stroke or transient ischemic attack. 
  • Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial. 
  • Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. 
  • Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. 
  • Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. 
  • Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. 
  • Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. 
  • Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. 
  • Effects of cholesterol-lowering statins on the aqueous humor outflow pathway. 
  • Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS). 
  • Effects of ezetimibe, simvastatin and ezetimibe/simvastatin on correlations between apolipoprotein B, LDL cholesterol and non-HDL cholesterol in patients with primary hypercholesterolemia. 
  • Effects of intense low-density lipoprotein cholesterol reduction in patients with stroke or transient ischemic attack: the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. 
  • Effects of simvastatin on retinal structure and function of a high-fat atherogenic mouse model of thickened Bruch's membrane. 
  • Efficacy and Safety of Adding Ezetimibe to Statin Therapy Among Women and Men: Insight From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Efficacy and Safety of Alirocumab 150 mg Every 4 Weeks in Patients With Hypercholesterolemia Not on Statin Therapy: The ODYSSEY CHOICE II Study. 
  • Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher. 
  • Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. 
  • Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. 
  • Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. 
  • Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. 
  • Evaluation of the National Cholesterol Education Program Adult Treatment Panel III algorithm for selecting candidates for statin therapy: insights from the A to Z trial. 
  • Evidence for Feedback Regulation Following Cholesterol Lowering Therapy in a Prostate Cancer Xenograft Model. 
  • Evidence for the role of cell stiffness in modulation of volume-regulated anion channels. 
  • Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. 
  • Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. 
  • Ezetimibe plus a Statin after Acute Coronary Syndromes. 
  • Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study. 
  • Familial hypercholesterolemia: Detect, treat, and ask about family. 
  • HDL-raising strategies in the treatment of coronary artery disease: perspectives from the Armed Forces Regression Study. 
  • HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. 
  • Health beliefs and desire to improve cholesterol levels among patients with hyperlipidemia. 
  • Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. 
  • Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. 
  • Hyperlipidemia in children and adolescents. 
  • Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Impact of Insurance Status on Outcomes and Use of Rehabilitation Services in Acute Ischemic Stroke: Findings From Get With The Guidelines-Stroke. 
  • Impact of increases in high-density lipoprotein cholesterol on cardiovascular outcomes during the armed forces regression study. 
  • In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y. 
  • Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. 
  • Inflammatory mechanisms. 
  • Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial. 
  • Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply. 
  • Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. 
  • Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease. 
  • Lipid profile, lipid-lowering medications, and intracerebral hemorrhage after tPA in get with the guidelines-stroke. 
  • Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. 
  • Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. 
  • Long-term Safety and Efficacy of Achieving Very Low Levels of Low-Density Lipoprotein Cholesterol : A Prespecified Analysis of the IMPROVE-IT Trial. 
  • Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. 
  • Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. 
  • Medical economics and the assessment of value in cardiovascular medicine: Part II. 
  • Muscle Complaints or Events in Patients Randomized to Simvastatin or Ezetimibe/Simvastatin. 
  • Nonpharmacologic and pharmacologic treatment of patients with low levels of high-density lipoprotein cholesterol. 
  • Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development. 
  • On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT). 
  • Overcoming inertia: improvement in achieving target low-density lipoprotein cholesterol. 
  • PCSK9 Inhibitor Use in the Real World: Data From the National Patient-Centered Research Network. 
  • PCSK9 inhibitors for prevention of atherosclerotic cardiovascular disease. 
  • Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT). 
  • Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial. 
  • Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. 
  • Pharmacological and surgical treatments for obesity. 
  • Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial. 
  • Population Effect of Differences in Cholesterol Guidelines in Eastern Europe and the United States. 
  • Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. 
  • Premature release of data from clinical trials of ezetimibe. 
  • Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). 
  • Probucol increases glutathione peroxidase-1 activity and displays long-lasting protection against methylmercury toxicity in cerebellar granule cells. 
  • Probucol prevents early coronary heart disease and death in the high-density lipoprotein receptor SR-BI/apolipoprotein E double knockout mouse. 
  • Psychometric Properties of the Four-Item Morisky Green Levine Medication Adherence Scale among Atherosclerosis Risk in Communities (ARIC) Study Participants. 
  • Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics. 
  • Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. 
  • Rationale and design of the Statins Evaluation in Coronary procedUres and REvascularization: The SECURE-PCI Trial. 
  • Recommendations for use of ezetimibe and/or PCSK9 inhibitors in patients with elevated LDL-C. 
  • Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial. 
  • Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects? 
  • Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. 
  • Regulation of Cholesterol Homeostasis by Hedgehog Signaling in Osteoarthritic Cartilage. 
  • Relation of lumen size to restenosis after percutaneous transluminal coronary balloon angioplasty. Lovastatin Restenosis Trial Group. 
  • Relations of GlycA and lipoprotein particle subspecies with cardiovascular events and mortality: A post hoc analysis of the AIM-HIGH trial. 
  • Relationship of lipoproteins to cardiovascular events: the AIM-HIGH Trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides and Impact on Global Health Outcomes). 
  • Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. 
  • Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial. 
  • Reply: Adding Ezetimibe to Simvastatin for the Secondary Prevention of Cardiovascular Disease: Is it Useful? 
  • Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML). 
  • Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT". 
  • Results from a practice-based lipid clinic model in achieving low density lipoprotein cholesterol goals. 
  • Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. 
  • Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. 
  • Safety considerations with gastrointestinally active lipid-lowering drugs. 
  • Selective biliary secretion of basal and glucagon-inhibited neutral sterol after triparanol administration. 
  • Separating the mechanism-based and off-target actions of cholesteryl ester transfer protein inhibitors with CETP gene polymorphisms. 
  • Session highlights from the American College of Cardiology Scientific Sessions: March 29 to April 1, 1998. 
  • Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. 
  • Statins after intracerebral hemorrhage: to treat or not to treat. 
  • Statins and cognition: what can we learn from existing randomized trials? 
  • Statins and other cholesterol-lowering medications and the presence of glaucoma. 
  • Statins inhibit toll-like receptor 4-mediated lipopolysaccharide signaling and cytokine expression. 
  • Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. 
  • Synthes Award for Resident Research in Spinal Cord & Spinal Column Injury: Statins for the treatment of neurological injury: a role beyond cholesterol lowering. 
  • Synthesis of C3 heteroatom-substituted azetidinones that display potent cholesterol absorption inhibitory activity. 
  • Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 
  • Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy. 
  • The Current Evidence for Lipid Management in Patients with Lower Extremity Peripheral Artery Disease: What Is the Therapeutic Target? 
  • The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial. 
  • The effect of gemfibrozil, niacin and cholestyramine combination therapy on metabolic syndrome in the Armed Forces Regression Study. 
  • The effects of cholesterol lowering with simvastatin on cause-specific mortality and on cancer incidence in 20,536 high-risk people: a randomised placebo-controlled trial [ISRCTN48489393]. 
  • The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. 
  • Therapy and clinical trials. 
  • Therapy and clinical trials. 
  • Timing of Loading Dose of Atorvastatin in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndromes: Insights From the SECURE-PCI Randomized Clinical Trial. 
  • Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? 
  • Treatment of hyperlipidemia by specialists versus generalists as secondary prevention of coronary artery disease. 
  • Treatment of hyperlipidemia with combined niacin-statin regimens. 
  • Unearthing the Janus-face cholesterogenesis pathways in cancer. 
  • Universal Cholesterol Screening in Childhood: A Systematic Review. 
  • Use of atorvastatin in systemic lupus erythematosus in children and adolescents. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Schanberg, Laura Eve, Professor of Pediatrics, Pediatrics, Rheumatology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics